NCT04458363 is a EARLY_PHASE1 clinical trial of Convalescent Plasma (CP) in COVID, sponsored by Emory University.

Who is sponsoring NCT04458363?

NCT04458363 is sponsored by Emory University.

What drugs are being tested in NCT04458363?

Interventions in NCT04458363: Convalescent Plasma (CP), Standard COVID-19 therapies.

Is NCT04458363 still recruiting?

NCT04458363 is currently completed. Last updated 22 November 2021.

Last reviewed 2021-11-22 · How we verify

NCT04458363

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Convalescent Plasma in Pediatric COVID-19

Completed EARLY_PHASE1 Last updated 22 November 2021

What this trial tests

EARLY_PHASE1 trial testing Convalescent Plasma (CP) in COVID in 3 participants. Completed in 1 September 2020.

Timeline

4 July 2020

Primary endpoint
1 September 2020

1 September 2020

Quick facts

Lead sponsor	Emory University
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	4 July 2020
Primary completion	1 September 2020
Estimated completion	1 September 2020
Sites	1 location across United States

Drugs / interventions tested

Convalescent Plasma (CP) — full drug profile →
Standard COVID-19 therapies — full drug profile →

Conditions studied

COVID — all drugs for COVID →

Sponsor

Emory University

Who can join

Adults 0 to 22, any sex, with COVID. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

COVID-19 is increasingly affecting children but convalescent plasma (CP) has not been adequately studied in children to date. The study will determine safety of convalescent plasma for pediatric patients with severe, or at high risk for severe, COVID-19 disease.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V, Iannizzi C, Chai KL, Valk SJ, et al · · 2021 · cited 106× · PMID 34013969 · DOI 10.1002/14651858.cd013600.pub4
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 24× · PMID 36734509 · DOI 10.1002/14651858.cd013600.pub5
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 21× · PMID 37162745 · DOI 10.1002/14651858.cd013600.pub6
The use of convalescent plasma for pediatric patients with SARS-CoV-2: A systematic literature review.
Zaffanello M, Piacentini G, Nosetti L, Franchini M. · · 2021 · cited 20× · PMID 33388249 · DOI 10.1016/j.transci.2020.103043
Acute severe respiratory syndrome coronavirus-2 treatment overview for pediatrics.
Murphy ME, Clay G, Danziger-Isakov L, Schulert G, et al · · 2021 · cited 3× · PMID 33394741 · DOI 10.1097/mop.0000000000000983

Verify or expand the search:

Other trials of Convalescent Plasma (CP)

Trials testing the same drug.

NCT04476888 — Convalescent Plasma Treatment in COVID-19 · NA · completed

Other recruiting trials for COVID

Currently open trials in the same condition.

NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test · NA · recruiting
NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
NCT04447833 — Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome · Phase 1 · active not recruiting
NCT04351347 — The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment · Phase 2, PHASE3 · recruiting
NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting

Other Emory University trials

Trials by the same sponsor.

NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04458363 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emory University
Last refreshed: 22 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04458363.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing